Stockscreener 앱 받기
15.97
0.31%
0.05
전일 마감가:
$15.92
열려 있는:
$16.02
하루 거래량:
28,972
Relative Volume:
0.12
시가총액:
$92.63M
수익:
$858.00K
순이익/손실:
$-7.82M
주가수익비율:
-11.01
EPS:
-1.4503
순현금흐름:
$-27.59M
1주 성능:
+0.31%
1개월 성능:
+13.26%
6개월 성능:
+156.65%
1년 성능:
+512.16%
1일 변동 폭
$15.79
$16.23
1주일 범위
$15.76
$16.45
52주 변동 폭
$2.40
$17.57
Rallybio Corp Stock (RLYB) Company Profile
명칭
Rallybio Corp
전화
203- 859-3820
주소
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
15.97 | 92.63M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-17 | 개시 | H.C. Wainwright | Buy |
| 2023-04-10 | 개시 | Wedbush | Outperform |
| 2022-12-09 | 개시 | JP Morgan | Overweight |
| 2022-02-22 | 개시 | JMP Securities | Mkt Outperform |
| 2021-08-23 | 개시 | Cowen | Outperform |
| 2021-08-23 | 개시 | Evercore ISI | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
모두보기
Rallybio Corp 주식(RLYB)의 최신 뉴스
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corp (RLYB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
Rallybio Company Profile & Introduction - Moomoo
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
JOHNSON & JOHNSON's Rallybio Corp(RLYB) Holding History - GuruFocus
San Diego Biotech Upstart Avenzo Plots Nasdaq Splash In Rallybio Reverse Merger - Hoodline
United StatesMintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction - Mondaq
Avenzo Picks Up Reverse Merger Ditched by Candid - San Diego Business Journal
ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB) - Stock Titan
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock - Investing.com
Mintz Advising on $215 Million Private Placement Concurrent with Avenzo Therapeutics’ and Rallybio’s Merger Transaction - Mintz
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - Business Wire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corpo - GuruFocus
Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing - The Pharma Letter
Rallybio to Raise $215M Via Pvt Placement >RLYB - Moomoo
Rallybio: Placement Expected to Fund Ops Into Late 2028 >RLYB - Moomoo
Rallybio: Combined Co Expected to Operate As Avenzo Therapeutics >RLYB - Moomoo
RLYB: Merger leverages oncology expertise and $215M funding to advance clinical programs and milestones - TradingView
RLYB: Merger accelerates oncology pipeline with $215M funding and late 2028 cash runway - TradingView
Rallybio finds a new reverse-merger dance partner in Avenzo - FirstWord Pharma
RallyBio tries again for reverse merger, this time with Avenzo - BioPharma Dive
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders - marketscreener.com
RLYB: Rallybio to Merge with Avenzo Therapeutics in Strategic Ac - GuruFocus
EDGAR Filing Documents for 0001193125-26-249801 - SEC.gov
Rallybio and Avenzo Therapeutics Announce Merger and $215 Million Private Placement to Advance Next-Generation Oncology Therapies – Minichart - Minichart
Rallybio to merge with Avenzo Therapeutics in $215M deal - grafa.com
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing - Endpoints News
After failed deal, Rallybio announces new merger; New Haven HQ to close - Hartford Business Journal
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
Rallybio to Merge With Avenzo Therapeutics in Oncology-Focused Reverse Merger Backed by $215 Million Financing - citybiz
Rallybio swerves past Candid pothole to land deal with Avenzo - Fierce Biotech
Rallybio to acquire Avenzo in $215 million merger deal By Investing.com - Investing.com South Africa
Rallybio Corp (RLYB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):